SeaStar Medical Holding Corp. (ICU) has a clinical trial catalyst to watch this quarter involving its proprietary selective cytopheretic device in adult patients with acute kidney injury requiring continuous kidney replacement therapy.
A multicenter, randomized, controlled, pivotal study assessing the safety and efficacy of a selective cytopheretic device in patients with acute kidney injury requiring continuous kidney replacement therapy, dubbed NEUTRALIZE-AKI, is underway. The study is now over 60% enrolled, with 125 of 200 anticipated patients.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.